MYLA software. Used to manage microbiology test workflow from the reception of requests to the transmission of results by transferring, storing, and displaying medical device data.
Published August 18, 2021 · Recall initiated: June 22, 2021
Summary
FDA records medical device Class II recall Z-2225-2021, published August 18, 2021 and initiated June 22, 2021. Recalling firm: BioMerieux SA; Status: Terminated; Reported quantity: 248 systems; Lot: MYLA V4.8.0/4.8.1 and MYLA V4.7.0/V4.7.1 in conjunction with BCI CONNECT, UDI 03573026619244 and 03573026610975. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Software anomaly - Under certain conditions, unwanted alterations to results could be applied when using the BCI Connect scripting feature.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- BioMerieux SA
- Distributor
- Distribution in the U.S. was nationwide. There was also military and government distribution.
- Lot
- MYLA V4.8.0/4.8.1 and MYLA V4.7.0/V4.7.1 in conjunction with BCI CONNECT, UDI 03573026619244 and 03573026610975.
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- France
Related recalls
- FDAEMAG system Model/Catalog Number: 418591/418591U Product Description: Nucleic acid sample preparationNovember 4, 2026
- FDAProform- support surface is used to assist in the prevention and treatment of all categories/stages ofAugust 18, 2021
- FDAGrasper/Retriever, Alligator Jaw, Rat Tooth 2.4 mm x 8 mm x 230 cm Catalog Number: 7226 Intended use: singleAugust 18, 2021
- FDAVIDAS FSH, Ref 30407-01, IVD, Rx. The firm name on the label is bioMerieux SA, France. For use on theJuly 4, 2018
- FDAThe VITEK® 2 Gram Positive Susceptibility Card is intended for use with the VITEK 2 Systems in clinicalJune 20, 2018
- FDAETEST OXACILLIN OX 256 US F100 In vitro diagnostic, a quantitative technique for determining the antimicrobialDecember 27, 2017
Questions about this recall
Was MYLA software. Used to manage microbiology test workflow from the reception of requests to the transmission of results by transferring, storing, and displaying medical device data. recalled?
Yes. FDA published recall Z-2225-2021 on August 18, 2021. Reported hazard: Software anomaly - Under certain conditions, unwanted alterations to results could be applied when using the BCI Connect scripting feature.
What should I do if I have this product?
Voluntary: Firm initiated · Letter